机构名称：
¥ 1.0
第二行处理选项 *在以下情况下a）至e）： （tofacitinib +mtx，upadacitinib +/- mtx）或apremilast +/- mtx或其他口服dmard或IL- 23抑制剂（Guselkumab，risankizumab，risankizumab）+/- mtx（N.B.使用利济氏菌的其他标准 - 中度至重度的牛皮癣（至少3％的身体表面积受斑块牛皮癣影响和牛皮癣面积和严重程度指数[PASI]得分大于10）b） +/- MTX，或考虑“ A”场景中列出的治疗方案。c) If previously treated with TNF Inhibitor+/- MTX AND inadequate response after 12 weeks: Consider the treatment options stated in scenario ‘ b ' d) If previous treatment was not a TNF Inhibitor +/- MTX, AND inadequate response after 12 weeks: Consider switching to a TNF inhibitor +/- MTX or the alternate treatment options stated in scenario ‘a ' e) If TNF inhibitor is contra-indicated: Consider IL-17A inhibitor (Secukinumab *** , Ixekizumab ** , Bimekizumab) +/- MTX, or IL-12/23 inhibitor (Ustekinumab) +/- MTX or JAK Inhibitor ∞ (Tofacitinib + MTX, or , Upadacitinib +/- MTX) Apremilast (+/- MTX或另一个口服DMARD）或IL-23抑制剂（Guselkumab，risankizumab）+/- MTX（请参见上文 - 其他标准适用于Risankizumab）
主动牛皮癣关节炎的治疗途径（...
主要关键词
相关文件推荐
